Children's Oncology Group's 2023 blueprint for research: Neuroblastoma
Pediatric Blood & Cancer · 2023-09 · 70 (S6)
DOI: 10.1002/pbc.30572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 17.07.2023. Verfasst von Rochelle Bagatell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Neuroblastoma. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, U.S. Department of Defense.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Neuroblastoma is the most common extra‐cranial solid tumor in children and is known for its clinical heterogeneity. A greater understanding of the biology of this disease has led to both improved risk stratification and new approaches to therapy. Outcomes for children with low and intermediate risk disease are excellent overall, and efforts to decrease therapy for such patients have been largely successful. Although survival has improved over time for patients with high‐risk disease and treatments evaluated in the relapse setting are now being moved into earlier phases of treatment, much work remains to improve survival and decrease therapy‐related toxicities. Studies of highly annotated biobanked samples continue to lead to important insights regarding neuroblastoma biology. Such studies, along with correlative biology studies incorporated into therapeutic trials, are expected to continue to provide insights that lead to new and more effective therapies. A focus on translational science is accompanied by an emphasis on new agent development, optimized risk stratification, and international collaboration to address questions relevant to molecularly defined subsets of patients. In addition, the COG Neuroblastoma Committee is committed to addressing the patient/family experience, mitigating late effects of therapy, and studying social determinants of health in patients with neuroblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
- Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
- Children's Oncology Group, Monrovia, California, USA.
- Department of Pediatrics, Children's Healthcare of Atlanta Inc Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, USA.
- Department of Oncology, St Jude Children's Research Hospital Department of Oncology, Memphis, Tennessee, USA.
ORCID-Profile: Rochelle Bagatell, Steven G DuBois, Meredith S Irwin
Förderung
- NCI NIH HHS
- U.S. Department of Defense
Zitieren
APA
Bagatell, R., DuBois, S. G., Naranjo, A., Belle, J., Goldsmith, K. C., Park, J. R., Irwin, M. S., & COG Neuroblastoma Committee (2023). Children's Oncology Group's 2023 blueprint for research: Neuroblastoma. Pediatric Blood & Cancer, 70(S6). https://doi.org/10.1002/pbc.30572
Vancouver
Bagatell R, DuBois SG, Naranjo A, Belle J, Goldsmith KC, Park JR, et al. Children's Oncology Group's 2023 blueprint for research: Neuroblastoma. Pediatric Blood & Cancer. 2023;70(S6). doi:10.1002/pbc.30572
BibTeX
@article{Bagatell2023,
author = {Bagatell, Rochelle and DuBois, Steven G and Naranjo, Arlene and Belle, Jen and Goldsmith, Kelly C and Park, Julie R and Irwin, Meredith S and COG Neuroblastoma Committee, COG Neuroblastoma Committee},
title = {Children's Oncology Group's 2023 blueprint for research: Neuroblastoma},
journal = {Pediatric Blood & Cancer},
year = {2023},
volume = {70},
number = {S6},
doi = {10.1002/pbc.30572}
}
EUVIMED